Long-awaited survival data for Dacogen (decitabine) failed to show a significant survival advantage compared to best supportive care in patients with myelodysplastic syndromes, sending shares of SuperGen Inc. down 14.6 percent while giving a boost to Celgene Corp., which markets competing demethylation agent Vidaza. (BioWorld Today)